Home » MIGRAINE
Category Archives: MIGRAINE
DRUG APPROVALS BY DR ANTHONY MELVIN CRASTO
.....FOR BLOG HOME CLICK HEREFlag and hits
ORGANIC SPECTROSCOPY
SUBSCRIBE
Subscribe in a reader
Enter your email address:
Delivered by FeedBurner
Subscribe to New Drug Approvals by Email
Recent Comments
 | shivkr2 on SPSR Excellence Award 2025 – S… |
 | Bonkasaurus on Infigratinib phosphate |
 | PALOVAROTENE | ORGAN… on Palovarotene |
| Pfizer just purchase… on Temanogrel | |
| Pfizer To Cash In On… on Temanogrel |
Refisolone
Refisolone
CAS202718-04-5
MFC18H24O3 MW288.4 g/mol
(1S,2S,4R,6S,7S,10S,11S)-11-hydroxy-7-methyl-5-oxapentacyclo[8.8.0.02,7.04,6.011,16]octadec-15-en-14-one
- (16alpha,17alpha)-16,17-Epoxy-10-hydroxyestr-4-en-3-one
- Estr-4-en-3-one, 16,17-epoxy-10-hydroxy-, (16alpha,17alpha)-
10-hydroxy-16α,17α-epoxyestr-4-en-3-one
GABAA receptor antagonist, migraine. PH 80, 2QA794326X
Refisolone (INNTooltip International Nonproprietary Name, USANTooltip United States Adopted Name; developmental code names PH-80, Salubrin, and ORG-39479), also known as 10-hydroxy-16α,17α-epoxyestr-4-en-3-one, is a vomeropherine (pherine) which is under development for the treatment of hot flashes, migraine, and premenstrual dysphoric disorder (PMDD).[1][2][4][3] It is taken intranasally as a nasal spray.[1][2][3] The pharmacology of refisolone has been studied and reported.[5][6] The drug is under development by Pherin Pharmaceuticals and VistaGen Therapeutics, with the former having been acquired by the latter in 2023.[1][2][4][3] As of December 2025, refisolone is in phase 2 clinical trials for all indications.[1][4] However, a phase 3 trial of refisolone for PMDD is also reported to have been registered in 2015, though its status is listed as unknown.[3][7]
Refisolone (developmental code name PH-80) is an investigational, non-hormonal pherine (vomeropherine) nasal spray currently in Phase 2 clinical trials for the treatment of menopausal hot flashes (vasomotor symptoms), migraines, and premenstrual dysphoric disorder (PMDD).
Mechanism of Action
Unlike conventional menopausal treatments, Refisolone does not rely on systemic hormone replacement. It is administered intranasally at microgram-level doses to achieve a rapid, on-demand effect. The spray works by activating chemosensory neurons in the nasal cavity, which send signals to the olfactory-limbic and olfactory-hypothalamic pathways in the brain to regulate anxiety and correct body temperature neural circuits.
Current Clinical Status
- FDA Status: The US FDA cleared the Investigational New Drug (IND) application for Refisolone, issuing a “Study May Proceed” letter to allow advanced Phase 2 trials to move forward.
- Development History: The compound was originally created by Pherin Pharmaceuticals, which was fully acquired by Vistagen Therapeutics.
- Clinical Trial Progress: A successful Phase 2a exploratory trial for menopausal hot flashes was completed in Mexico, showing that the compound was well-tolerated with no serious drug-related adverse events.
Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric DisorderCTID:
NCT01217775, Phase:Phase 3Status:Unknown status, Date:2015-12-03
PAT
WO2009126825
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2009126825&_cid=P21-MT2BVX-74335-1
The preparation of the estrene compound 16α,17α-epoxy-10β-hydroxyestr-4-en-3-one is described in commonly assigned US Pat. No. 6,057,439, which is incorporated herein by reference. The steroid compound 16α,17α-epoxy-10β-hydroxyestr-4-en-3-one has the chemical structure of:
PAT
WO2025217068
https://patentscope.wipo.int/search/en/detail.jsf?docId=WO2025217068&_cid=P21-MT2BVX-74335-2
16a, 17a epoxyestr-4 en-iop ol-3 one will not be associated with or cause endometrial effects such as endometrial hyperplasia or endometrial cancer as are associated with conventional estrogen therapies.
[0054] US Patent No. 6,057,439 (“US 6,057,439) describes the use of a number of steroidal pherines for the treatment of premenstrual dysphoric disorder and anxiety by administration to the vomeronasal organ of an individual suffering from those symptoms. Among the pherines described in U.S. Pat. 6,057,439 is 16a,17a-Epoxyestr-4-en-10|3-ol-3-one, which is also known in the art as PH80, has the following chemical structure:
.S. Pat. 6,057,439 also describes the synthesis of 16a,17a-Epoxyestr-4-en-10p-ol-3-one and pharmaceutical compositions containing it for alleviating symptoms of PMDD. U.S. Pat. 6,331,534 describes the same steroids for alleviating pain by vomeronasal administration. U.S. Pat. 8,431,559, “Treatment of hot flashes”, describes a synthesis of 16a,17a-epoxyestr-4-en-10p-ol-3-one, which it refers to as 16a,17a-epoxy-10p-hydroxyestr-4-en-3-one, and a method of using 16a,17a-epoxyestr-4-en-10p-ol-3-one to alleviating hot flashes by administering 16a,17a-epoxyestr-4-en-10p-ol-3-one via intranasal administration. U.S.
Pat. 11,419,881, “Treatment of migraine”, similarly describes a synthesis of 16a,17a-epoxyestr-4-en-10P-ol-3-one and also refers to the drug as 16a,17a-epoxy-10p-hydroxyestr-4-en-3-one. U.S. Pat. 11,419,881 also describes a method for alleviating migraines by nasally administering 16a,17a-epoxyestr-4-en-10p-ol-3-one .
PAT
- Treatment of migrainePublication Number:US-2020323884-A1Priority Date:2019-04-15
- Treatment of migrainePublication Number:EP-3955933-A1Priority Date:2019-04-15
- Treatment of migrainePublication Number:EP-3955933-B1Priority Date:2019-04-15Grant Date:2023-11-29
- Treatment of migrainePublication Number:WO-2020214452-A1Priority Date:2019-04-15
- Steroid treatment for hot flashesPublication Number:US-2009258040-A1Priority Date:2008-04-09
- Treatment of Hot FlashesPublication Number:US-2012108558-A1Priority Date:2008-04-09
- Steroid treatment for hot flashesPublication Number:WO-2009126825-A1Priority Date:2008-04-09
- Steroid treatment for hot flashesPublication Number:EP-2278880-A1Priority Date:2008-04-09
- Treatment of hot flashesPublication Number:US-8431559-B2Priority Date:2008-04-09Grant Date:2013-04-30
- Steroid treatment for hot flashesPublication Number:EP-2278880-B1Priority Date:2008-04-09Grant Date:2012-10-10
- Steroids as neurochemical stimulators of the vno to alleviate symptoms of pmsPublication Number:EP-0914165-B1Priority Date:1996-07-23Grant Date:2006-10-18
- Steroids as neurochemical stimulators of the VNO to alleviate symptoms of PMS and anxietyPublication Number:US-6057439-APriority Date:1994-08-04Grant Date:2000-05-02
- Steroids as neurochemical stimulators of the VNO to treat paroxistic tachycardiaPublication Number:US-6117860-APriority Date:1994-08-04Grant Date:2000-09-12
- Steroids as neurochemical stimulators of the VNO to alleviate painPublication Number:US-6331534-B1Priority Date:1994-08-04Grant Date:2001-12-18
ADVERISEMENT
ANAX LABORATORIES
WEBSITE https://www.anaxlab.com/
Discovery Solutions, Supporting the chemistry needs of clients in the Medical, Analytical and Bio Sciences
Development Solutions, Developing from Lab scale to PR&D, Kilo Scale-ups and Commercial Scales
SEE MORE………Integrated Solutions, Manufacturing Solutions, Products,
Can’t Find? Let’s Connect
Phone : +91 897704 2010 / +91 9177075735, Email : info@anaxlab.com
#MedicinalChemistry, #DrugDiscovery, #OrganicSynthesis, #ChemicalLibrary, #BuildingBlocks, #SARStudies, #ChemistryInnovation, #medchem, #Drugdevelopment, #Biotech, #Biotechnology, #AnaxLaboratories, #Pharma
AS ON FEB2026 4.574 LAKHS VIEWS ON BLOG WORLDREACH AVAILABLEFOR YOUR ADVERTISEMENT
join me on Linkedin
Anthony Melvin Crasto Ph.D – India | LinkedIn
join me on Researchgate
RESEARCHGATE
join me on Facebook
Anthony Melvin Crasto Dr. | Facebook
join me on twitter
Anthony Melvin Crasto Dr. | twitter
+919321316780 call whatsaapp
EMAIL. amcrasto@gmail.com
References
References
- “VistaGen Therapeutics”. AdisInsight. Springer Nature Switzerland AG. 2 December 2025. Retrieved 9 March 2026.
- “Pherin Pharmaceuticals”. AdisInsight. Springer Nature Switzerland AG. 28 July 2024. Retrieved 9 March 2026.
- “PH-80 Drug Profile”. Ozmosi. Retrieved 9 March 2026.
- “Delving into the Latest Updates on Refisolone”. Synapse. PatSnap. 28 February 2026. Retrieved 9 March 2026.
- Monti L, Baker RA, Hanover R (25 November 2025). Refisolone PH80 Nasal Spray Effects on In Vitro Receptor Binding, Reproductive Organs in Mice, and Pharmacokinetic Profile in Humans. The Menopause Society 2025 Annual Meeting.
- Monti L, Baker RA, Hanover R (25 November 2025). Refisolone PH80 Nasal Spray Effects on Brain and Autonomic Activity: A Novel, Investigational, Rapid-Onset Non-Hormonal Treatment for Vasomotor Symptoms Due to Menopause. The Menopause Society 2025 Annual Meeting.
- Clinical trial number NCT01217775 for “Intranasal PH80 Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder (PH80-PMD)” at ClinicalTrials.gov
External links
 | |
| Clinical data | |
|---|---|
| Other names | PH-80; PH80; PH-80-M; PH80-M; PH80M; PH80-PMD NS; PH80-HF; PH80-HF NS; Salubrin; Salubrin HF; ORG-39479; ORG39479; 10-Hydroxy-16α,17α-epoxyestr-4-en-3-one; 16α,17α-Epoxyestr-4-en-10-ol-3-one |
| Routes of administration | Intranasal (nasal spray)[1][2][3] |
| Drug class | Vomeropherine |
| Identifiers | |
| IUPAC name | |
| CAS Number | 202718-04-5 |
| PubChem CID | 21968346 |
| UNII | 2QA794326X |
| Chemical and physical data | |
| Formula | C18H24O3 |
| Molar mass | 288.387 g·mol−1 |
| 3D model (JSmol) | Interactive image |
| SMILES | |
| InChI | |
//////////refisolone, anax labs, GABAA receptor antagonist, migraine, PH 80, 2QA794326X
#refisolone, #anax labs, #GABAA receptor antagonist, #migraine, #PH 80, #2QA794326X
Rimegepant sulfate, リメゲパント硫酸塩;
Rimegepant
- Molecular FormulaC28H28F2N6O3
- Monoisotopic mass534.219116 Da
Antimigraine, Calcitonin receptor-like receptor antagonist
Treatment of migraine
|
Rimegepant sulfate (USAN)
リメゲパント硫酸塩; |
|
| Formula |
(C28H28F2N6O3)2. H2SO4. 3H2O
|
|---|---|
| CAS |
1374024-48-2
|
| Mol weight |
1221.2386
|
Nurtec ODT, FDA 2020, 2020/2/27 fda approved
Biohaven Pharmaceuticals developed Rimegepant, also known as BMS-927711, acquired in 2016 from Bristol-Myers Squibb, Rimegepant, also known as BMS-927711. Rimegepant is a potent, selective, competitive and orally active calcitonin gene-related peptide (CGRP) antagonist in clinical trials for treating migraine. Rimegepant has shown in vivo efficacy without vasoconstrictor effect; it is superior to placebo at several different doses (75 mg, 150 mg, and 300 mg) and has an excellent tolerability profile.
Rimegepant is a medication for the treatment of an acute migraine with or without aura (a sensory phenomenon or visual disturbance) in adults. However, it is not to be used prophylactically. In the US, it is marketed under the brand name, Nurtec ODT.[1]
It is not indicated for the preventive treatment of migraine.[1] It is taken by mouth, to dissolve on the tongue.[1] It takes effect within an hour and can provide relief for up to 48 hours, according to Biohaven. It is not a narcotic and has no addictive potential, and consequently will not be designated a controlled substance. It works by blocking CGRP receptors. 86% of patients did not require additional rescue medication within 24 hours of a single dose of Nurtec. All this info was obtained from a press release from Biohaven. (https://www.prnewswire.com/news-releases/biohavens-nurtec-odt-rimegepant-receives-fda-approval-for-the-acute-treatment-of-migraine-in-adults-301013021.html)
Rimegepant was approved for use in the United States as of February 27th, 2020 by the U.S. Food and Drug Administration (FDA) to be produced and marketed by Biohaven Pharmaceuticals.[2]
Charlie Conway, Chief Scientific Officer at Biohaven Pharmaceuticals
Vlad Coric, M.D., CEO at Biohaven
clip
https://www.biohavenpharma.com/investors/news-events/press-releases/02-27-2020
BIOHAVEN’S NURTEC™ ODT (RIMEGEPANT) RECEIVES FDA APPROVAL FOR THE ACUTE TREATMENT OF MIGRAINE IN ADULTS
NEW HAVEN, Conn., Feb. 27, 2020 /PRNewswire/ — Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) today announced that the U.S. Food and Drug Administration (FDA) has approved NURTEC™ ODT (rimegepant) for the acute treatment of migraine in adults. NURTEC ODT is the first FDA-approved product for Biohaven, a company dedicated to advancing innovative therapies for neurological diseases.
NURTEC™ ODT Convenient 8-count Package
.jpg)
NURTEC™ ODT zoom in showing one individual quick-dissolving tablet (not actual size)
A single quick-dissolving tablet of NURTEC ODT can provide fast pain relief and return patients to normal function within one hour, and deliver sustained efficacy that lasts up to 48 hours for many patients. NURTEC ODT disperses almost instantly in a person’s mouth without the need for water, offering people with migraine a convenient, discreet way to take their medication anytime and anywhere they need it. NURTEC ODT is not indicated for the preventive treatment of migraine. Biohaven expects topline results from its prevention of migraine trial later this quarter.
Vlad Coric, M.D., CEO of Biohaven commented, “The FDA approval of NURTEC ODT marks an important milestone for the migraine community and a transformative event for Biohaven. Millions of people suffering from migraine are often not satisfied with their current acute treatment, at times having to make significant tradeoffs because of troublesome side effects and reduced ability to function. NURTEC ODT is an important new oral acute treatment for migraine that offers patients the potential to quickly reduce and eliminate pain and get back to their lives.” Dr. Coric added, “We believe NURTEC ODT will be the first of many innovative Biohaven medicines to become available to treat devastating neurological diseases, a therapeutic category many other companies have abandoned. We are dedicated to helping patients with these conditions, who often have limited or no treatment options, live better, more productive lives.”
NURTEC ODT, with its novel quick-dissolve oral tablet formulation, works by blocking CGRP receptors, treating a root cause of migraine. NURTEC ODT is not an opioid or narcotic, does not have addiction potential and is not scheduled as a controlled substance by the U.S. Drug Enforcement Administration.
NURTEC ODT may offer an alternative treatment option, particularly for patients who experience inadequate efficacy, poor tolerability, or have a contraindication to currently available therapies. More than 3,100 patients have been treated with rimegepant with more than 113,000 doses administered in clinical trials, including a one-year long-term safety study. In the pivotal Phase 3 trial, NURTEC ODT was generally well tolerated; the most common adverse reaction was nausea (2%) in patients who received NURTEC ODT compared to 0.4% of patients who received placebo.
Mary Franklin, Executive Director of the National Headache Foundation commented, “Everyone knows someone living with migraine, yet it remains an invisible disease that is often overlooked and misunderstood. Almost all people with migraine need an acute treatment to stop a migraine attack as it occurs, which can happen without warning. The approval of NURTEC ODT is exciting for people with migraine as it provides a new treatment option to help people regain control of their attacks and their lives.”
Peter Goadsby, M.D., Ph.D., Professor of Neurology and Director of the King’s Clinical Research Facility, King’s College Hospital commented, “I see many patients in my practice whose lives are disrupted by migraine, afraid to go about everyday life in case of a migraine attack. Many feel unsure if their acute treatment will work and if they can manage the side effects. With the FDA approval of NURTEC ODT, there is renewed hope for people living with migraine that they can get back to living their lives without fear of the next attack.”
The FDA approval of NURTEC ODT is based on results from the pivotal Phase 3 clinical trial (Study 303) and the long-term, open-label safety study (Study 201). In the Phase 3 trial, NURTEC ODT achieved statistical significance on the regulatory co-primary endpoints of pain freedom and freedom from most bothersome symptom (MBS) at two hours post dose compared to placebo. NURTEC ODT also demonstrated statistical superiority at one hour for pain relief (reduction of moderate or severe pain to no pain or mild pain) and return to normal function. The benefits of pain freedom, pain relief, return to normal function and freedom from MBS were sustained up to 48 hours for many patients. Importantly, these benefits were seen with only a single dose of NURTEC ODT. Eighty-six percent of patients treated with NURTEC ODT did not require rescue medication (e.g. NSAIDS, acetaminophen) within 24 hours post dose. The long-term safety study assessed the safety and tolerability of rimegepant with multiple doses used over up to one year. The study evaluated 1,798 patients, who used rimegepant 75 mg as needed to treat migraine attacks, up to one dose per day. The study included 1,131 patients who were exposed to rimegepant for at least six months, and 863 who were exposed for at least one year, all of whom treated an average of at least two migraine attacks per month. The safety of treating more than 15 migraines in a 30-day period has not been established.
NURTEC ODT is contraindicated in patients with a history of hypersensitivity to rimegepant, NURTEC ODT, or to any of its components. Hypersensitivity reactions with dyspnea and severe rash, including delayed serious hypersensitivity days after administration, occurred in less than 1% of subjects taking NURTEC ODT in clinical studies.
Biohaven Conference Call Information
Biohaven is hosting a conference call and webcast on Friday, February 28, 2020, at 8:00 a.m. ET. Participants are invited to join the conference by dialing 877-407-9120 (toll-free) or 412-902-1009 (international). To access the audio webcast with slides, please visit the “Events & Presentations” page in the Investors section of the Company’s website.
Biohaven’s Commitment to Patient Access
Biohaven is committed to supporting the migraine community by eliminating barriers to medication access. The company has launched a patient support program. For more information and to enroll, please call 1-833-4-NURTEC or visit www.nurtec.com.
NURTEC ODT will be available in pharmacies in early March 2020 in packs of eight tablets. Each eight tablet pack covers treatment of eight migraine attacks with one dose, as needed, up to once daily. Sample packs containing two tablets will also be made available to healthcare providers. Patients with migraine should discuss with their primary care provider or neurologist whether NURTEC ODT is appropriate for them.
About NURTEC ODT
NURTEC™ ODT (rimegepant) is the first and only calcitonin gene-related peptide (CGRP) receptor antagonist available in a quick-dissolve ODT formulation that is approved by the U.S. Food and Drug Administration (FDA) for the acute treatment of migraine in adults. The activity of the neuropeptide CGRP is thought to play a causal role in migraine pathophysiology. NURTEC ODT is a CGRP receptor antagonist that works by reversibly blocking CGRP receptors, thereby inhibiting the biologic activity of the CGRP neuropeptide. The recommended dose of NURTEC ODT is 75 mg, taken as needed, up to once daily. For more information about NURTEC ODT, visit www.nurtec.com.
About Migraine
Nearly 40 million people in the U.S. suffer from migraine and the World Health Organization classifies migraine as one of the 10 most disabling medical illnesses. Migraine is characterized by debilitating attacks lasting four to 72 hours with multiple symptoms, including pulsating headaches of moderate to severe pain intensity that can be associated with nausea or vomiting, and/or sensitivity to sound (phonophobia) and sensitivity to light (photophobia). There is a significant unmet need for new acute treatments as more than 90 percent of migraine sufferers are unable to work or function normally during an attack.
About CGRP Receptor Antagonism
Small molecule CGRP receptor antagonists represent a novel class of drugs for the treatment of migraine. This unique mode of action potentially offers an alternative to current agents, particularly for patients who have contraindications to the use of triptans, or who have a poor response to triptans or are intolerant to them.
What is NURTEC ODT?
NURTEC™ ODT (rimegepant) is indicated for the acute treatment of migraine with or without aura in adults.
Raising the “flag of freedom from migraine” over Biohaven headquarters in New Haven CT
Mechanism of action
Rimegepant is a small molecule calcitonin gene-related peptide (CGRP) receptor antagonist.[3]
PATENTS
WO 2011046997
PATENT
WO 2012050764
https://patents.google.com/patent/WO2012050764A1
The disclosure generally relates to a synthetic process for preparing compounds of formula I including the preparation of chemical intermediates useful in this process. CGRP inhibitors are postulated to be useful in pathophysiologic conditions where excessive CGRP receptor activation has occurred. Some of these include neurogenic vasodilation, neurogenic inflammation, migraine, cluster headache and other headaches, thermal injury, circulatory shock, menopausal flushing, and asthma. CGRP antagonists have shown efficacy in human clinical trials. See Davis CD, Xu C. Curr Top Med Chem. 2008 8(16):1468-79; Benemei S, Nicoletti P, Capone JG, Geppetti P. Curr Opin Pharmacol 2009 9(1):9-14. Epub 2009 Jan 20; Ho TW, Ferrari MD, Dodick DW, Galet V, Kost J, Fan X, Leibensperger H, Froman S, Assaid C, Lines C, Koppen H, Winner PK. Lancet. 2008 372:2115. Epub 2008 Nov 25; Ho TW, Mannix LK, Fan X, Assaid C, Furtek C, Jones CJ, Lines CR, Rapoport AM; Neurology 2008 70: 1304. Epub 2007 Oct 3.
CGRP receptor antagonists have been disclosed in PCT publications WO 2004/092166, WO 2004/092168, and WO 2007/120590. The compound (5S,6S,9R)- 5-amino-6-(2,3-difluorophenyl)-6,7,8!9-tetrahydiO-5H-cyclohepta[b]pyridin-9-yl 4- (2-oxo-2,3-dihydiO-lH-imidazo[4,5-b]pyridin-l-yl)piperidine-l-carboxylate is an inhibitor of the calcitonin gene-related peptide (CGRP) receptor.
cheme 1 illustrates a synthesis of formula I compounds. heme 1,
DESCRIPTION OF SPECIFIC EMBODIMENTS
( 6S, 9R)-6~ (2, 3 -difluorophenyl)-9-(triisopropylsiIyloxy) – 6, 7, 8, 9-tetrahydro-5H- cyclohepta[b]pyridin-5 -amine. To a 100 mL hastelloy autoclave reactor was charged (6S,9R)-6-(2,3-difluorophenyl)-9-(triisopiOpylsilyloxy)-6,7,8,9-tetrahydi -5H- cyclohepta[b]pyridin-5-one (5.00 g, 1 1.22 mmol), 1,4-dioxane (50 mL) and titanium tetra(isopropoxide) (8.33 mL, 28.11 mmol). The reactor was purged three times with nitrogen and three times with ammonia. After the purge cycle was completed, the reactor was pressurized with ammonia to 100 psig. The reaction mixture was heated to 50°C (jacket temperature) and stirred at a speed to ensure good mixing. The reaction mixture was aged at 100 psig ammonia and 50°C for 20 h. The mixture was then cooled to 20°C then 5 % Pd/Alumina (1.0 g, 20 wt%) was charged to the autoclave reactor. The reactor was purged three times with nitrogen and three times with hydrogen. After the purged cycle completed, the reactor was pressurized with hydrogen to 100 psig and mixture was heated to 50°C (jacket temperature) and stirred at a speed to ensure good mixing. The reaction mixture was aged at 100 psig H2 and 50°C for 23h (reactor pressure jumped to -200 psig due to soluble ammonia in the mixture). The mixture was then cooled to 20 °C then filtered then transferred to a 100 ml 3-necked flask. To the mixture water (0.55 mL) was added drop wise, which resulted in yellow slurry. The resulting slurry was stirred for 30 mm then filtered, then the titanium dioxide cake was washed with 1,4-dioxane (30 mL). The filtrate was collected and the solvent was removed. The resulting oil was dissolved in isopropanol (40 mL). To the solution ~5N HC1 in isopropanol (9.0 ml) was added drop wise resulting in a thick slurry. To the slurry isopropyi acetate (60 ml) was added and heated to 45 °C for 10 min and then cooled to 22 °C over approximately 3 h to afford a white solid (3.0 g, 51.5 %). Ή NMR (500 MHz, CD3OD)
δ ppm 8.89 (d, J= 5.3, 1H), 8,42 (bs, 1H), 8.05 (bs, 1H), 7.35 (dd, J= 8.19 , 16.71), 7.2 (bs, 2H), 7.22 (m, 1H) 7.15 (m, 1H), 5.7 (dd, J = 1.89, J = 8.51), 5.4 (m, 1H), 3.5 ( m, 1H), 1.9-2.5 (B, 4h) 1.4 (sept, J = 15.13,3H), 1.2 (t, J= Ί.5Ί 18H); 13C NMR (125 MHz, CD3OD) δ 153.5, 151.6, 151.5, 151.3, 149.4, 143.4, 135.03, 129.8, 129.8, 127.8, 126.8, 126.4, 118.6, 72.4, 54.1, 41.4, 34.3, 32.3, 25.4, 18.6, 18.5, 13.7, 13.6, 13.5, 13.3.
Example 2
(6S,9R)-5-cmino-6-(2 -difluorophenyl)-6, 7,8,9-tetrahydro~5H-cyclohepta[b^ 9-o To a 250 ml flask was charged (6S,9R)-6-(253-difluoiOphenyl)-9-
(tnisopiOpylsilyloxy)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-5-amine di HC1 salt (15 g, 25.88 mtnol) and a solution of isopropanol: water (45 mL : 15 mL). The mixture was heated to 82 °C for 6h then dried via azeotropic distillation at atmospheric pressure using isopropanol until the KF was less than < 3 %. After fresh isopropanol (25 ml) was added, the mixture was heated to 70 °C and then isopropyl acetate (45 ml) was added that resulting in a white slurry. The slurry cooled to 22 °C for 15 min to afford a white solid (9.33 g, 99%). 1H NMR (500 MHz CD3OD) δ 8.77 (d, J= 5.7 Hz, 1H), 8.47 (d, J= 7.9 Hz, 1H), 8.11 (dd, J= 6.0, 8.2 Hz, 1H), 7.21-7.32 (m, 3H), 5.53 (dd, J= 3.8, 9.8 Hz, 1H) 5.33 (d, J = 9.8 Hz, 1H), 3.5 (bm, 1H), 2.25- 2.40 (m, 2H), 2.15 (bm, 1H), 1.90 (bm, 1H); 13C NMR (125 MHz, MeOD) δ 159.4, 153.9, 151.9 and 151.8, 149.7, 143.6, 141.8, 135.7, 130.6, 127.7, 126.8, 1 18.9, 70.0, 54.9, 42.2, 34.5, 33.4. Example 3
(5S, 6S, 9R)-5-amino-6-(2, 3-difluorophenyl)-6, 7>8,9-tetrahydro-5H- cyclohepta[b ]pyridin-9~yl~4-(2-oxo-2, 3-dihydro-lH-imidazo[4, 5-b ]pyridin-l- yl)piperidine-l-carboxylate. To a round bottom flask was charged (5S,6S,9R)-5- amino-6-(2,3-difluorophenyl)-6,7,8,9-tetrahydro-5H-cyclohepta[b]pyridin-9-ol dihydrochloride (1.00 g, 2.73 mmol) and dichloromethane (15 mL). A solution of sodium carbonate (0.58 g, 5.47 mmol), 20 wt% aqueous sodium chloride (5 mL), and water (10 mL) was added and the biphasic mixture was aged for 30 min. The phases were allowed to separate and the organic stream was retained. The dichloromethane solvent was then switched with azeotropic drying to tetrahydrofuran, with a final volume of (15 mL). At 20 °C was added, l-(l-(lH~imidazole-l-carbonyl)piperidin- 4-yl)-lH-imidazo[4,5-b]pyridin-2(3H)-one (0.95 g, 3.01 mmol), followed by a 20 wt% potassium ter/-butoxide solution in THF (4 mL, 6.20 mmol). The thin slurry was aged for lh, and then the reaction was quenched with the addition of 20 wt% aqueous sodium chloride (5 mL) and 20 wt% aqueous citric acid (2.5 mL). The layers were allowed to separate and the organic rich layer was retained. The organic layer was washed with 20 wt% aqueous sodium chloride (1 mL). The organic tetrahydrofuran stream was then concentrated in vacuo to afford an oil which was resuspended in dichloromethane (20 mL) and dried with MgS04. The
dichloromethane stream was concentrated in vacuo to afford an oil, which was crystallized from ethanohheptane to afford a white solid (1.14 g, 78.3%). LCMS: [M+H] = 535: 1H MR (600 MHz, 6-DMSO) δ 11.58 (IH, bs), 8.45 (IH, bd), 8.03 (IH, d, J= 7.3 Hz), 7.91 (IH, bs), 7.54 (IH, bd), 7.36 (IH, bm), 7.34 (IH, bm), 7.28 (IH, m), 7.21 (IH, m), 7.01 (IH, bs), 6.01 (IH, dd, J= 3.2, 9.8 Hz), 4.48 (IH, d, J= 9.5 Hz), 4.43 (IH, bm), 4.38 (IH, bm), 4.11 (IH, bm), 3.08 (IH, bm), 2.93 (IH, bm), 2.84 (IH, m), 2.62 (IH, bm), 2.20 (2H, bm), 2.13 (IH, bm), 2.12 (IH, bm), 1.75 (IH, bm), 1.72 (1H, bm), 1.66 (1H, bm); C NMR (125 MHz, i/6-DMSO) δ 156.6, 154.2, 153.0, 149.8, 148.1, 146.4, 143.5, 139.6, 137.4, 134.0, 132.8, 124.7, 124.5, 123.3, 122.2, 116.3, 115.0, 114.3, 73.7, 52.8, 50.0, 43.8, 43.3, 32.0, 30.3, 28.6; nip 255°C.
Example 4
l-(l-(lH^mdazole-l-carbonyl)piperidin-4-yl)-lH-imidazo
To a round bottom flask was added, Ι,Γ-carbonyldiimidazole (8.59 g, 51.4 mmoi), diisopropylethylamine (12.6 mL, 72.2 mmol) and tetrahydrofuran (100 niL). This mixture was warmed to 40°C and aged for 10 min, after which l-(piperidin-4-yl)-lH- imidazo[4,5-b]pyridin-2(3H)-one dihydrochloride (10 g, 34,3 mmol) was added. The slurry was aged at 40 °C for 3 h, and then upon reaction completion, the solvent was swapped to acetonitrile which afforded an off white solid (9.19 g, 85.9%). LCMS: [M+H] = 313; Ή NMR (400 MHz, 6-DMSO) δ 11.58 (1H, s), 8.09 (1H, s), 7.97 (1H, d, J= 8.0 Hz), 7.73 (1H, d, J= 4.0 Hz), 7.53 (1H, s), 7.05 (1H, s), 7.00 (1H, dd, J= 4.0, 8.0 Hz), 4.52, (1H, dd, J= 8.0, 12.0 Hz), 4.05 (2H, bd, J= 8,0 Hz), 3.31 (2H, m), 2.34 (2H, m), 1.82 (2H, bd, J = 12.0 Hz); 13C NMR (100 MHz, i/6~DMSO) δ 153.0, 150.4, 143.4, 139.8, 137.2, 128.9, 123.0, 1 18.7, 116.4, 115.2, 49.3, 45.1 , 28.5; mp 226°C.
Example 5
l-(l-(lH-imidazole-l-carbonyl)piperidin-4-yl)-lH-imidazo[4,5
To a 250 ml round bottom flask was added 3-N-piperidin-4-ylpyridine-2, 3 -diamine dihydrochloride (10 g, 52 mmol) and acetonitrile (100 mL). Triethyl amine (11.44 g, 1 13 mmol) and 1 , -Carbonyldiimidazole (18.34 g, 113 mmol) were added at ambient temperature and the mixture was stirred for 2 h. The solvent was evaporated under vacuum to—30 ml reaction volume and isopropyl acetate (50 mL) was added into the resulting sluny at 40°C. The slurry was cooled to 10-15 °C and then stirred for 1 h to afford an off white solid (10 g, 85%).
PATENT
US 20130225636
EP 2815749
PAPER
Journal of Medicinal Chemistry (2012), 55(23), 10644-10651.
https://pubs.acs.org/doi/full/10.1021/jm3013147
Calcitonin gene-related peptide (CGRP) receptor antagonists have demonstrated clinical efficacy in the treatment of acute migraine. Herein, we describe the design, synthesis, and preclinical characterization of a highly potent, oral CGRP receptor antagonist BMS-927711 (8). Compound 8 has good oral bioavailability in rat and cynomolgus monkey, attractive overall preclinical properties, and shows dose-dependent activity in a primate model of CGRP-induced facial blood flow. Compound 8 is presently in phase II clinical trials.
PAPER
Organic letters (2015), 17(24), 5982-5.
https://pubs.acs.org/doi/full/10.1021/acs.orglett.5b02921
An asymmetric synthesis of novel heterocyclic analogue of the CGRP receptor antagonist rimegepant (BMS-927711, 3) is reported. The cycloheptane ring was constructed by an intramolecular Heck reaction. The application of Hayashi–Miyaura and Ellman reactions furnished the aryl and the amine chiral centers, while the separable diastereomeric third chiral center alcohols led to both carbamate and urea analogues. This synthetic approach was applicable to both 6- and 5-membered heterocycles as exemplified by pyrazine and thiazole derivatives.
History
Originally discovered at Bristol-Myers Squibb,[4] it was under development by Biohaven Pharmaceuticals and is now also being marketed in the US by the same company after receiving FDA approval late February 2020.[5]
References
- ^ Jump up to:a b c “Nurtec ODT (rimegepant) orally disintegrating tablets, for sublingual or oral use” (PDF). February 2020. Retrieved 27 February 2020.
- ^ “Nurtec ODT: FDA-Approved Drugs”. U.S. Food and Drug Administration (FDA). Retrieved 28 February 2020.
- ^ Diener HC, Charles A, Goadsby PJ, Holle D (October 2015). “New therapeutic approaches for the prevention and treatment of migraine”. The Lancet. Neurology. 14 (10): 1010–22. doi:10.1016/S1474-4422(15)00198-2. PMID 26376968.
- ^ “Rimegepant – Biohaven Pharmaceuticals Holding Company”. Adis Insight. Springer Nature Switzerland AG.
- ^ “Rimegepant (BHV-3000) – for acute treatment of Migraine”. Biohaven Pharmaceuticals.
External links
- “Rimegepant”. Drug Information Portal. U.S. National Library of Medicine.
- Clinical trial number NCT03461757 for “Trial in Adult Subjects With Acute Migraines” at ClinicalTrials.gov
 |
|
| Clinical data | |
|---|---|
| Trade names | Nurtec ODT |
| Other names | BHV-3000, BMS-927711 |
| License data |
|
| Routes of administration |
By mouth |
| Drug class | calcitonin gene-related peptide receptor antagonist |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard(EPA) | |
| Chemical and physical data | |
| Formula | C28H28F2N6O3 |
| Molar mass | 534.568 g·mol−1 |
| 3D model (JSmol) | |
//////////Rimegepant , リメゲパント硫酸塩, Rimegepant sulfate, migraine, BMS-927711, fda 2020
New Drug Approvals 
